查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1794458

全球月经药物市场

Menstrual Drugs
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 290 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年全球月经药物市场规模将达 124 亿美元

全球月经药物市场规模预计在2024年达到84亿美元，预计在2024-2030年的分析期内将以6.8%的复合年增长率增长，到2030年将达到124亿美元。激素类药物是本报告分析的细分市场之一，预计其复合年增长率将达到6.5%，到分析期结束时将达到48亿美元。止痛药细分市场在分析期间内的复合年增长率预计为7.8%。

美国市场规模估计为 23 亿美元，中国市场预计复合年增长率为 10.6%

美国月经药物市场规模预计2024年达到23亿美元。作为世界第二大经济体，中国预计到2030年市场规模将达到26亿美元，在分析期间（2024-2030年）的复合年增长率为10.6%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间的复合年增长率分别为3.4%和6.6%。在欧洲，德国的复合年增长率预计为4.5%。

全球月经药物市场－主要趋势与驱动因素摘要

为什么月经药物在女性保健领域受到如此广泛的认可？

随着全球对月经健康认识的提高以及围绕月经的偏见逐渐消退，月经药物越来越被认为是女性整合保健的重要组成部分。这些药物旨在控制各种与月经有关的症状，包括经痛、月经（大量出血）、月经症候群（PMS）和月经症候群（月经月经于荷尔蒙避孕药或非处方止痛药，但更有针对性的药物的发展扩大了可用的治疗范围。非类固醇消炎剂（NSAID）、荷尔蒙疗法、解痉药和血清素再回收抑制剂常用的处方药，可针对特定症状提供各种解决方案。随着女性在生殖健康管理方面更加积极主动，已开发国家和开发中国家对月经药物的需求都在增加。教育宣传活动、社群媒体宣传以及医疗保健提供者的倡导，正在进一步打破围绕月经的文化沉默。各国政府和非政府组织也越来越多地将月经管理纳入其公共卫生工作，尤其是在学校健康计画和以女性为中心的推广活动中。这些共同的努力正在创造一种环境，使卫生药物不再被视为可有可无的，而是被视为女性身心和社会福祉的核心。

药物创新如何改变月经药物的有效性和安全性？

医药领域的进步正在提升月经药物的疗效和安全性，在改善患者预后和增强患者对治疗方案的信心方面发挥关键作用。其中最重要的进展之一是荷尔蒙治疗方法的演变，如今荷尔蒙疗法的剂量更低，给药机制也更具针对性，从而在最大程度提高疗效的同时最大限度地减少副作用。延长週期的口服避孕药、释放荷尔蒙的避孕器(IUD) 和经皮贴片为患有慢性月经失调的女性提供了长期解决方案。同时，新一代非类固醇消炎剂(NSAID) 的胃肠道耐受性得到改善，它们正在被引入，以更安全地缓解月经，尤其是长期使用。生物技术也促进了月经健康的创新，相关研究正在探索基因表现和荷尔蒙调节，以更好地理解和治疗子宫内膜异位症和经前烦躁症 (PMDD) 等疾病。此外，数位疗法和基于应用程式的平台开始与药物解决方案相结合，帮助女性追踪症状并优化治疗时机，从而获得最大益处。药物研发人员越来越注重个人化医疗方法，并意识到月经健康状况受遗传、生活方式和并存健康状况的影响差异很大。此外，他们也正在努力开发非荷尔蒙疗法，以应对无法或不愿使用荷尔蒙的女性，进一步扩大治疗的整体性。这些创新不仅提高了月经药物的治疗价值，也减少了先前与长期治疗计画相关的犹豫和恐惧，尤其是在青少年和首次使用者中。

文化规范和当地医疗保健如何影响月经药物的采用？

文化信念、医疗基础设施和当地认知程度显着影响着世界各地对月经药物的接受程度。在已开发国家，医疗保健服务相对普及，女性健康话题也更加普遍，常规妇科护理和药物的广泛供应为月经药物的使用提供了支持。相较之下，在许多开发中地区和低收入地区，社会文化禁忌、宗教限制和错误讯息仍然阻碍女性就医治疗月经失调。因此，许多女性选择家庭疗法或默默忍受症状，延误了诊断和治疗。然而，由于倡导团体、国际卫生组织以及旨在使月经世俗化和促进月经平等的教育宣传活动的努力，这种趋势正在逐渐改变。行动诊所、学校健康计画和远端医疗平台正在改善农村和服务匮乏人群获得月经药物和资讯的管道。经济因素也会影响女性接受长期治疗的能力。一些国家的政府已开始对月经药物提供补贴或将其纳入基本药物清单，鼓励其更广泛地使用并纳入初级卫生保健服务。此外，将月经健康教育纳入学校课程，也使年轻女性掌握了相关知识，并增强了她们的信心，从而能够更早地寻求医疗协助。这些不断变化的社会动态正在逐步重塑月经药物市场，使其更具包容性，并更好地应对地区多样性和医疗保健差异。

加速全球月经药物市场成长的关键驱动因素有哪些？

月经药物市场的成长受到多种相互关联的趋势的推动，包括医疗政策、药物创新、消费行为和社会变革。首先，多囊性卵巢症候群、子宫内膜异位症和严重月经等月经紊乱疾病的盛行率不断上升，这推动了对有效药物介入的临床需求。其次，已开发市场和新兴市场医疗保健管道的扩大和保险覆盖范围的扩大，使月经治疗更加经济实惠且更加普及。第三，随着社会变得更加开放，月经耻辱感正在消除，越来越多的女性开始寻求医疗解决方案，而不是默默忍受痛苦。第四，包括非荷尔蒙药物和植物来源药物开发在内的多样化治疗方案正在吸引更多具有不同需求和偏好的使用者。第五，数位健康平台的扩展促进了远距咨询和个人化治疗计划的製定，使女性更容易开始和管理自己的治疗。第六，由以女性为中心的品牌和健康组织主导的有针对性的行销宣传活动和宣传活动正在教育消费者并提高产品知名度。第七，公营和私人公司对女性健康的投资不断增加，加速了更安全、更有效的月经疗法的研发。最后，将月经健康纳入全球生殖健康和保健议程，巩固了月经在长期医疗保健规划中的重要性。这些驱动力共同造就了更成熟、更有韧性的月经药物市场，支持全球采取积极主动、稳健的月经健康管理方法。

部分

药物类型（荷尔蒙治疗、缓解疼痛、PMS/PMDD 治疗、月经调节、其他药物类型）、给药途径（口服、注射给药、局部给药）

受访公司范例

  • Abbott Laboratories
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Cadila Healthcare（Zydus）
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals
  • HRA Pharma（a Perrigo company）
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.（MSD）
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global 特定产业产业SLM 的典型规范，而是建立了一个从世界各地专家收集的内容库，包括影片录影、部落格、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP37367

Global Menstrual Drugs Market to Reach US$12.4 Billion by 2030

The global market for Menstrual Drugs estimated at US$8.4 Billion in the year 2024, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Hormonal Treatment Drugs, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Pain Relief Drugs segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 10.6% CAGR

The Menstrual Drugs market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Menstrual Drugs Market - Key Trends & Drivers Summarized

Why Are Menstrual Drugs Gaining Broader Acceptance in Women’s Healthcare?

Menstrual drugs are increasingly being recognized as essential components of comprehensive women’s healthcare, as global awareness about menstrual health rises and stigmas surrounding menstruation continue to erode. These medications are designed to manage a wide array of menstrual-related conditions such as dysmenorrhea (painful periods), menorrhagia (heavy bleeding), premenstrual syndrome (PMS), and premenstrual dysphoric disorder (PMDD). For many women, these drugs significantly improve quality of life by reducing pain, regulating cycles, and stabilizing mood fluctuations. Traditionally, the treatment of menstrual issues was limited to hormonal contraceptives or over-the-counter pain relievers, but the development of more targeted pharmaceutical options has expanded the therapeutic landscape. Non-steroidal anti-inflammatory drugs (NSAIDs), hormonal therapies, antispasmodics, and serotonin reuptake inhibitors are now commonly prescribed, offering diverse solutions tailored to specific symptoms. As women become more proactive about managing their reproductive health, the demand for menstrual drugs is growing across both developed and developing regions. Educational campaigns, social media awareness, and healthcare provider advocacy have further reduced the cultural silence surrounding menstruation. Governments and NGOs are also increasingly including menstrual management as part of public health initiatives, especially in school health programs and women-focused outreach. These collective efforts are creating an environment where menstrual drugs are no longer viewed as optional but are instead recognized as central to women's physical, emotional, and social well-being.

How Are Pharmaceutical Innovations Transforming the Effectiveness and Safety of Menstrual Drugs?

Pharmaceutical advancements are playing a critical role in enhancing both the effectiveness and safety profile of menstrual drugs, leading to better patient outcomes and greater confidence in treatment options. One of the most significant developments is the evolution of hormone-based therapies, which are now being engineered with lower doses and more targeted delivery mechanisms to minimize side effects while maximizing efficacy. Extended-cycle oral contraceptives, hormone-releasing intrauterine devices (IUDs), and transdermal patches are offering long-term solutions for women with chronic menstrual disorders. In parallel, newer generations of NSAIDs with improved gastrointestinal tolerability are being introduced to manage menstrual pain more safely, especially for long-term use. Biotechnology is also contributing to innovation in menstrual health, with research exploring gene expression and hormonal modulation to better understand and treat conditions like endometriosis and PMDD. Additionally, digital therapeutics and app-based platforms are beginning to be paired with pharmacological solutions, helping women track symptoms and optimize treatment timing for maximum benefit. Drug developers are increasingly focusing on personalized medicine approaches, recognizing that menstrual health varies widely based on genetics, lifestyle, and co-existing health conditions. Efforts are also underway to develop non-hormonal therapies for women who are unable or unwilling to use hormonal drugs, further broadening treatment inclusivity. These innovations are not only improving the therapeutic value of menstrual drugs but also reducing the hesitation or fear previously associated with long-term treatment plans, especially among adolescents and first-time users.

How Do Cultural Norms and Regional Healthcare Access Influence the Adoption of Menstrual Drugs?

Cultural beliefs, healthcare infrastructure, and regional awareness levels greatly influence the adoption of menstrual drugs across different parts of the world. In developed countries, where healthcare access is relatively widespread and conversations around women’s health are more normalized, the usage of menstrual drugs is supported by routine gynecological care and broad pharmaceutical availability. In contrast, in many developing and low-income regions, socio-cultural taboos, religious restrictions, and misinformation still hinder women from seeking medical assistance for menstrual disorders. As a result, many women rely on home remedies or endure symptoms in silence, delaying diagnosis and treatment. However, this trend is gradually changing, thanks to the efforts of advocacy groups, international health organizations, and educational campaigns aimed at destigmatizing menstruation and promoting menstrual equity. Mobile clinics, school-based health programs, and telemedicine platforms are improving rural and underserved populations’ access to menstrual drugs and information. Economic factors also play a role, as the affordability of drugs influences whether women can commit to long-term treatment. Governments in some countries are beginning to subsidize or include menstrual drugs in essential medicine lists, which is encouraging broader use and integration into primary healthcare services. Furthermore, the inclusion of menstrual health education in school curricula is equipping young women with the knowledge and confidence to seek medical help early. These shifting social dynamics are steadily reshaping the menstrual drug market, making it more inclusive and responsive to regional diversity and healthcare disparities.

What Are the Main Drivers Accelerating the Growth of the Global Menstrual Drugs Market?

The growth in the menstrual drugs market is driven by several interrelated trends across healthcare policy, pharmaceutical innovation, consumer behavior, and societal change. First, the rising prevalence of menstrual disorders such as PCOS, endometriosis, and severe dysmenorrhea is fueling clinical demand for effective pharmaceutical interventions. Second, increasing healthcare access and insurance coverage in both developed and emerging markets are making menstrual treatments more affordable and widespread. Third, greater societal openness and the destigmatization of menstruation are encouraging more women to seek medical solutions rather than suffer in silence. Fourth, the diversification of treatment options, including the development of non-hormonal and plant-based drugs, is attracting a wider range of users with different needs and preferences. Fifth, the expansion of digital health platforms is facilitating remote consultations and personalized treatment plans, making it easier for women to initiate and manage their care. Sixth, targeted marketing campaigns and awareness initiatives led by women-centric brands and health organizations are educating consumers and improving product visibility. Seventh, increased investment in women’s health by both public agencies and private pharmaceutical companies is accelerating research and development of safer, more effective menstrual therapies. Lastly, the integration of menstrual health into global reproductive health and wellness agendas is cementing its importance in long-term healthcare planning. Collectively, these drivers are contributing to a more mature and resilient menstrual drug market, one that supports a proactive and empowered approach to managing menstrual health around the world.

SCOPE OF STUDY:

The report analyzes the Menstrual Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs, Other Drug Types); Administration Route (Oral Administration, Injectable Administration, Topical Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Cadila Healthcare (Zydus)
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals
  • HRA Pharma (a Perrigo company)
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Menstrual Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Menstrual Health Throws the Spotlight on Therapeutic Solutions for Pain and Cycle Regulation
    • Increased Diagnosis of Conditions Like Endometriosis and PCOS Propels Growth in Hormonal and Anti-Inflammatory Drug Use
    • Growing Demand for Non-Opioid Pain Relief Expands the Addressable Market Opportunity for NSAIDs and Natural Alternatives
    • Shift Toward Over-the-Counter and Self-Care Solutions Strengthens the Business Case for Easily Accessible Menstrual Medications
    • Evolving Societal Attitudes Toward Menstrual Wellness Accelerate Demand for Targeted, Symptom-Specific Drugs
    • Product Innovation in Extended-Release and Combination Formulations Drives Adoption Among Younger Demographics
    • Rising Use of Oral Contraceptives for Menstrual Management Spurs Dual-Benefit Drug Utilization
    • Telehealth and DTC Women's Health Platforms Throw the Spotlight on Digital Access to Menstrual Prescriptions
    • Increased Focus on Quality of Life and Workplace Productivity Supports Greater Use of Period Pain Medications
    • Demand for Plant-Based and Hormone-Free Menstrual Relief Products Drives Growth in Complementary Therapies
    • Clinical Interest in Personalized Medicine and Hormone Profiling Expands Potential for Tailored Menstrual Drug Regimens
    • Menstrual Tracking Apps and Digital Health Tools Generate Insights That Spur Demand for Proactive Pharmaceutical Interventions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Menstrual Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hormonal Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Pain Relief Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for PMS & PMDD Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Menstrual Regulation Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • JAPAN
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CHINA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • EUROPE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • FRANCE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • GERMANY
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • INDIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AFRICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030

IV. COMPETITION